OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian CancerTopline results to be ...
Corvus Pharmaceuticals develops immuno-oncology therapies, advancing clinical candidates for cancer and immune-related ...
Cancer is a highly complex disease that tends to be caused by the overgrowth of malignant cells and altered immune response. Traditional cancer therapies include surgery, radiotherapy, chemotherapy, ...
Healthcare Asia Magazine on MSN
Immunotherapy boom drives demand for PET/CT imaging in Australia’s oncology sector
Australia accounted for 2% of the APAC PET/CT market in 2025. Australia’s PET/CT systems market is expected to grow at a 5% ...
Lugano, Switzerland, 2 December 2024 – The ESMO Immuno-Oncology Congress 2024 will take place in Geneva, Switzerland, from December 11-13, with an option to attend virtually. Leading experts will ...
Merck & Co.’s PD1 blocker pembrolizumab is a force to be reckoned with. Already a US$15 billion per year antibody, it is on track to becoming industry’s top-selling product by 2023. Approved for ...
This article was published in Scientific American’s former blog network and reflects the views of the author, not necessarily those of Scientific American In 2017 the first immuno-oncology cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results